The Importance of Pharmaceutical Care in Oncologic Patients Undergoing Oral Antineoplastic Treatment: A Pilot Study on Adherence, Quality of Life, and Perceptions of the Information Received

Ferrari, G.; Visacri, Marília Berlofa; Quintanilha, Júlia Coelho França; Vito, Gabriela Galhardo de; Barbosa, Cristina Rosa; Dias, Lara Paro; Lima, Carmen Sílvia Passos; Moriel, Patrícia

doi:10.1177/1062860617737158

Cited by 3 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…33,34 Home therapy has the advantage of being more accepted and preferred than intravenous treatment, though exposes patients to management issues that could engender loss of adherence to treatment. 35 In the field of Oncology, data on treatment adherence varies widely, as they range from a minimum of 23% to a maximum of 100%. 36 This variability may be explained by the type of disease and its treatment, as well as the choice of analysis method and the type and number of sample analyzed.…”

Section: Discussionmentioning

confidence: 99%

Adherence to and effectiveness of lenalidomide after 1 year of treatment in a real world setting

Santoleri

Lasala

Ranucci

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

Background In combination with dexamethasone, lenalidomide is prescribed in the oral treatment of Multiple Myeloma for patients who have received at least one previous therapy. Objective The objective of this study is to evaluate medication adherence to lenalidomide of Multiple Myeloma patients, as well as Progression Free Survival and Overall Survival one year from the beginning of the treatment. Setting The study was carried out in Pescara Hospital, in Italy. All Multiple Myeloma patients who began lenalidomide therapy between January 1, 2012 and June 30, 2016 were included in our study. Methods Adherence to treatment was calculated by using the ratio between the Received Daily Dose and the Prescribed Daily Dose. Effectiveness in real world has been evaluated as Progression Free Survival and Overall Survival one year from the beginning of the treatment. Main outcomes measure: We assessed medication adherence and effectiveness of lenalidomide in the treatment of Multiple Myeloma. Results Adherence to the overall mean treatment was 0.73 ± 0.15, relative to 81 patients evaluated in our study. 32% of patients achieved an adherence equal to or greater than 80%. Real-life effectiveness in terms of Progression Free Survival and Overall Survival showed values of 53.75% and 88%, respectively, one year from the beginning of treatment. Conclusion The analysis of adherence in Multiple Myeloma patients treated with lenalidomide one year from the beginning of therapy reveal a concerning lack of adherence. Moreover, the lack of correlation of the levels of adherence with patient-related variables shows that, in the case of Multiple Myeloma, adherence is not related to personal, social and environmental characteristics that may determine each patient’s correct treatment implementation, but is directly influenced by disease evolution.

show abstract

Section: Discussionmentioning

confidence: 99%

Adherence to and effectiveness of lenalidomide after 1 year of treatment in a real world setting

Santoleri

Lasala

Ranucci

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…Patient counseling and medication management for oncologic patients receiving oral anticancer treatment is necessary to increase adherence, identify and manage common adverse drug reactions, and improve the quality of life. 8 As a result of the significant increase in the use of oral therapies in cancer management worldwide, the postmarketing surveillance is essential. Concerned about this issue, we recently have investigated toxicity, adherence and quality of life in hepatocellular carcinoma patients taking sorafenib, another oral anticancer drug.…”

Section: Introductionmentioning

confidence: 99%

Adverse reactions and adherence to capecitabine: A prospective study in patients with gastrointestinal cancer

Visacri

Duarte

Lima

et al. 2021

J Oncol Pharm Pract

Self Cite

View full text Add to dashboard Cite

Introduction Capecitabine is an oral anticancer drug which can cause some adverse reactions and the great challenge for its use is to ensure the medication adherence. The aim of this study was to analyze adverse reactions and adherence to capecitabine in patients with gastrointestinal cancer. Methods A prospective study was performed in a tertiary teaching hospital in Brazil. Outpatients undergoing capecitabine treatment for colorectal or gastric cancer were followed for three cycles of treatment. Patient demographic and clinical characteristics data were collected. Adverse reactions were analyzed using Common Terminology Criteria for Adverse Events (CTCAE) v.4. Adherence to capecitabine were evaluated using Morisky-Green and MedTake tests. Statistical analysis was conducted using Chi‐square, Fisher's exact and McNemer tests. Results One hundred and four patients were enrolled in this study, with a mean age was 58.5 ± 10.9 years; 51.0% were men and 51.0% Caucasian. Nausea and diarrhea were the most frequently reported adverse reactions (82.7% and 62.5%, respectively), followed by vomiting (54.8%), fatigue (54.8%), and hand-foot syndrome (53.9%). Nausea and diarrhea were also the most severe adverse reactions. Most patients were adherent to capecitabine in all cycles of treatment using the Morisky-Green test. Adherence increased significantly between cycle 1 and cycle 2 by MedTake test (p < 0.001). Some demographic and clinical characteristics were associated with adverse reactions (e.g., age and nausea, gender and nausea and vomiting) and capecitabine adherence (e.g., marital status and educational level) as well as some adverse reactions were associated with capecitabine adherence (hand-foot syndrome and nausea). Conclusions Clinical oncology pharmacists must provide patient information on the correct use of capecitabine, manage adverse reactions, and monitor adherence to treatment. Strategies to prevent non-adherence to capecitabine must be adopted to ensure the success of pharmacotherapy.

show abstract

Outcomes in hepatocellular carcinoma patients undergoing sorafenib treatment: toxicities, cellular oxidative stress, treatment adherence, and quality of life

Ferrari¹,

Quintanilha²,

Visacri³

et al. 2020

Anti-Cancer Drugs

View full text Add to dashboard Cite

The study of toxicities induced by sorafenib, as well as the identification of possible mechanisms and biomarkers of these toxicities, is important to improve the treatment and quality of life of hepatocellular carcinoma (HCC) patients. This study focused on toxicities, cellular oxidative stress, adherence, and quality of life of 11 patients with HCC treated with sorafenib. Dermatotoxicity, myelotoxicity, gastro toxicity, nephrotoxicity, pain, and fatigue were investigated. For oxidative stress analysis, the peripheral blood mononuclear cells were isolated and mitochondrial superoxide anion production was measured using MitoSOX Red test. Medication adherence was evaluated based on Morisky-Green and MedTake tests. Quality of life assessment was performed using EORTC QLQ C-30 and QLQ HCC18 questionnaires. The results showed that hand-foot syndrome (45.5%), thrombocytopenia (45.5%), diarrhea (54.5%), pain (54.5%), and fatigue (36.4%) were the most prevalent toxicities. A non-statistically significant change in the levels of superoxide anion was observed after the sorafenib treatment (Wilcoxon test, P = 0.4131). Moreover, 81.8% of patients had high adherence, 100% knew the correct indication of sorafenib, 81.8% knew the correct intake and drug regimen, and 36.4% knew the correct dose of antineoplastic. There was a significant worsening in the emotional and pain domains of quality of life after the sorafenib (Wilcoxon test, P = 0.0313 and P = 0.0313, respectively). A production of superoxide anion was not correlated with toxicities (Spearman’s correlation and Mann–Whitney U tests, P > 0.05). This study suggests that oxidative stress might not be the mechanism of sorafenib toxicities.

show abstract

The Importance of Pharmaceutical Care in Oncologic Patients Undergoing Oral Antineoplastic Treatment: A Pilot Study on Adherence, Quality of Life, and Perceptions of the Information Received

Cited by 3 publications

References 6 publications

Adherence to and effectiveness of lenalidomide after 1 year of treatment in a real world setting

Adherence to and effectiveness of lenalidomide after 1 year of treatment in a real world setting

Adverse reactions and adherence to capecitabine: A prospective study in patients with gastrointestinal cancer

Outcomes in hepatocellular carcinoma patients undergoing sorafenib treatment: toxicities, cellular oxidative stress, treatment adherence, and quality of life

Contact Info

Product

Resources

About